Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
271
datasets available to search
ShareScore release 0.9.0
Dataset results
271 results for “Adrenal gland”
A spatiotemporal regulatory network for steroidogenesis of human fetal adrenal glands and gonads
GEO Series GSE167860. Homo sapiens. 18 samples. Type: Expression profiling by high throughput sequencing.
Expression data from mouse adrenal glands extracted from wild-type and sf1:Cre; Prkar1a Fl/Fl (KO) adrenals
GEO Series GSE77630. Mus musculus. 8 samples. Type: Expression profiling by array.
Changes of gene expression in adrenal gland after Ephb6 gene knockout in mice
GEO Series GSE120400. Mus musculus. 18 samples. Type: Expression profiling by array.
Microarray study of aldosterone-producing adenomas (APA) and their adjacent normal adrenal glands
GEO Series GSE156931. Homo sapiens. 24 samples. Type: Expression profiling by array.
Influence of form of Se supplementation and tall fescue endophyte toxicity on the adrenal gland transcriptome of grazing beef steers
GEO Series GSE198583. Bos taurus. 32 samples. Type: Expression profiling by array.
Hormonal Regulation of MicroRNA Expression in Rat Adrenal Gland
GEO Series GSE47131. Rattus norvegicus; synthetic construct. 12 samples. Type: Expression profiling by array.
Dataset related to article "Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis "
<p>This record contains raw data related to article “Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis"</p> <p> </p> <p>Adrenal metastases occur in 15-35% of oncological patients. Surgery is the first treatment option. Stereotactic body radiotherapy (SBRT) has been largely explored in oligometastatic patients unfit for surgery, representing an effective and non-invasive local treatment. The results of a multi-institutional experience of SBRT on adrenal metastases in the oligorecurrent or oligoprogressive setting are herein reported. We collected data of adrenal gland metastases treated with SBRT in three Italian centers from 2010 to 2020. End-points of the present study were: Overall survival (OS), Local control of treated metastases (LC), Progression free survival (PFS), and toxicity. 149 adrenal gland metastases were treated with SBRT in 142 patients. The most common primary tumor was lung cancer (58.4%), followed by kidney cancer (9.4%). Median lesion's volume was 28.5 cm<sup>3</sup> (2.5-323.4). The median SBRT dose was 40 Gy (10-60). Median follow-up was 14.4 months. One- and two-year OS were 72.3% and 53.5%. At univariate analysis performance status correlated with survival (HR 1.57, p = 0.006). One- and two-year LC were 85.4% and 79.2%, with lung primary tumor (HR 0.33, p = 0.021) and BED10 (HR 0.97, p = 0.036) significant independent factors. One- and two-year PFS were 37.7% and 24.8%. Median time to polymetastatic disease was 11.3 months. Grade 1 and 2 toxicity occurred in 21 (14.7%) and 3 (2.1%) patients. The results from this large multi-center study confirm the efficacy and safety of SBRT in the management of adrenal gland metastases, as a valid alternative to other more invasive local approaches.</p>
Dataset related to article "Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production "
<p>This record contains raw data related to article "Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production"</p> <p><strong>Purpose: </strong> The purpose of this study was to assess prospectively the efficacy and safety of stereotactic body radiation therapy (SBRT) for adrenal gland metastasis, with a focus on the assessment of the irradiated subjects' endocrinological function.</p> <p><strong>Materials and methods: </strong> A total of 36 patients were enrolled from 2017 to 2020 in this prospective phase II trial. Patients were treated with Linac-based SBRT, with a dose of 45 Gy in 3 consecutive fractions. Primary end-point was local control (LC) of the treated lesions and secondary end-points included evaluation of acute and late toxicity, progression free survival (PFS), overall survival (OS) and the impact on the hormonal production of adrenal glands.</p> <p><strong>Results: </strong> With a median follow-up of 9.5 months, LC rates at 1 and 2 years were 94.7% and 88.4%, respectively. Rates of PFS at 1 and 2 years were 50.5% and 29.8%, with a median PFS of 14.7 months. Rates of OS at 1 and 2 years were 62.9% and 44.1%. At univariate analysis, oligorecurrence was associated with better OS compared to oligoprogressive or synchronous metastatic disease. No grade 3 or greater toxicities were registered and only a minority of patients (22.2%) reported mild treatment-related side effects. Hormonal and electrolytes production was assessed before and after treatment, showing only a slight and transient variation within the reference ranges.</p> <p><strong>Conclusion: </strong> SBRT on adrenal metastases has been confirmed to be a feasible and effective treatment. With an excellent disease control and the preservation of the endocrine function, SBRT with ablative dose can be considered a viable alternative to more invasive approaches.</p>
Influence of form of Se supplementation and tall fescue endophyte toxicity on the adrenal gland and kidney transcriptome of grazing beef steers
GEO Series GSE198589. Bos taurus. 64 samples. Type: Expression profiling by array.
Expression data from mouse adrenal gland at 2 month of age
GEO Series GSE194211. Mus musculus. 4 samples. Type: Expression profiling by array.
The effect of Crem absence on gene expression in mouse adrenal glands.
GEO Series GSE29592. Mus musculus. 10 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.